Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in oligodendrocytes (1441 nCPM) | 1.00 |
| chemistry Open Targets | compounds already reach it: oncolysin s, lorvotuzumab mertansine | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 13 Parkinson's papers of 623 | 0.65 |
| pathways Reactome | 6 pathways; mostly immune signalling | 0.90 |
Knock down and overexpress NCAM1 in oligodendrocytes; measure IL-1β and TNF release and surface HLA-DR and α-synuclein uptake and myelin basic protein output under oxidative stress.
- Cell type
- oligodendrocytes
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- IL-1β and TNF release and surface HLA-DR
- Functional readout
- α-synuclein uptake and myelin basic protein output under oxidative stress
- Rule-out
- If neither arm moves IL-1β by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of NCAM1 in iPSC-derived oligodendrocytes; n = 3 differentiations; readouts: IL-1β and TNF release and surface HLA-DR; α-synuclein uptake and myelin basic protein output under oxidative stress. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- NCAM1 in dopamine neurons, braak-0.07 (p 0.855) → +0.12 (p 0.756)receipt 3129
- NCAM1 in oligodendrocytes, braak+0.05 (p 0.892) → +0.29 (p 0.443)receipt 3128
Swarm cases
receipt 3129: NCAM1 in dopamine neurons, braak
- power
- full sample +0.15 (p 0.555, n 18), 95% CI -0.34 to +0.58. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.10 (p 0.690, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.14 (p 0.567, n 18). could be the mix.
- skeptic
- leave-one-out range +0.05 to +0.33, sign flips 0; without severely affected donors +0.15 (p 0.555, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NCAM1 in dopamine neurons.
case closed: nothing better to follow up.
receipt 3128: NCAM1 in oligodendrocytes, braak
- power
- full sample +0.06 (p 0.800, n 18), 95% CI -0.42 to +0.52. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.01 (p 0.962, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.14 (p 0.579, n 18). could be the mix.
- skeptic
- leave-one-out range -0.04 to +0.19, sign flips 4; without severely affected donors +0.06 (p 0.800, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for NCAM1 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts